Metastatic Osteosarcoma Treatment Market – Drivers And Market Insights

Osteosarcoma or bone cancer is a type of cancer were bone tissues show an abnormal growth. Osteosarcoma that spreads from initially affected area to distant site is known as metastatic osteosarcoma. Metastatic osteosarcoma often spreads to lungs, whereas less commonly spreads to other bones, brain or other organs. Symptoms of metastatic osteosarcoma varies based on the location of tumor, for example bone pain, bone fracture, swelling, redness, limping, and limited joint movement. If the tumor spreads to the lungs the symptoms include chest pain, shortness of breath, cough with blood, chronic coughing or wheezing. Diagnostic tests for metastatic osteosarcoma includes CT-scan, MRI, X-ray, PET scan, biopsy, and bone scan. Treatment of metastatic osteosarcoma involves surgery, radiation, chemotherapy, biological therapy or a combination of these treatments. Combinational treatment also known as multi-modality treatment is more preferred by medical practitioners to increase treatment outcomes or to prolong survival.

Click To Continue Reading On Metastatic Osteosarcoma Treatment Market

Metastatic Osteosarcoma Treatment Market – Drivers

Increasing drug pipeline for malignant bones and soft tissue (Ewing Sarcoma) cancer is expected to drive growth of metastatic osteosarcoma treatment market. For instance, in 2017, Merck & Co., Inc., studies the effects of Pembrolizumab (MK-3475) in patients with relapsed or metastatic osteosarcoma and reported that these patient are not eligible for curative surgery. Currently, study is in phase II clinical trial and is expected to be marketed in 2023. Moreover, Novartis entered into phase II clinical trials for pazopanib for treatment of metastatic osteosarcoma as of March 2018.

Emerging new therapies for metastatic osteosarcoma treatment will further propel growth of the market. For instance, clinical trials for immunotherapy-based drugs and targeted drug therapy is expected to be a preferred option in the near future, owing to less side-effects. The immune therapy drug called immune checkpoint inhibitors can recognize and attack cancer cells exhibiting better outcomes for other cancer types and also studies have showed it is also effective for osteosarcoma treatment. Moreover, engineered monoclonal antibodies are used to stop cancer growth by hampering new blood vessel formation or to inhibit tumor cells by targeting mTOR protein. For instance, Aadi, LLC studies Nivolumab (Opdivo) in combination with ABI-009 (Nab-rapamycin, the mTOR inhibitor) for potential anti-tumor activity for Ewing Sarcoma. The study is in phase II clinical trial, which is expected to complete by 2020.

Get The Holistic SAMPLE With Research Methodology:

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702“>

Visit our news Website:

Write a Comment

Your email address will not be published. Required fields are marked *